Advancing Drug Development with Non-Liquid Matrix Bioanalysis

At Veloxity Labs, we're pushing the boundaries of bioanalytical science by focusing on non-liquid matrices (NLMs)—tissues, cells and other solid biological materials that reveal drug behavior right at the site of action. This capability is especially vital for cutting-edge therapies like gene and cell therapies, oncolytic viruses and nucleic acid-based drugs.

This report builds on insights from a pivotal white paper in The AAPS Journal, exploring how industry leaders are tackling the complexities of NLMs and outlining our approach to method development, standardization and regulatory alignment. Whether you're optimizing PK assays or exploring biomarkers, Veloxity is leading the charge to transform NLM bioanalysis into a new standard for next-gen therapeutics.

Download the Report